Financials

  • Market Capitalization 770.86 M
  • Employee 116
  • Founded 1994
  • CEO Craig A Tooman
  • Website www.silence-therapeutics.com
  • Headquarter United Kingdom
  • FIGI BBG00WVTHPN2
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-20.85
Price to sales ratio
22.07
Dividends per share
Dividend yield %

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

Notícias